Content - Collaboration PG New Anticancer Treatments with companies

Collaboration PG New Anticancer Treatments with companies

The aim of the SAKK New Anticancer Treatments Project Group is to conduct drug development with new drugs in a cooperative setting in Switzerland. The SAKK provides a well established and experienced network of centers that are able to carry out Phase I trials and also first in human trials with new anticancer drugs. The main features regarding the collaboration between the New Anticancer Treatments Project Group and pharmaceutical companies are:

  • The activity of the New Anticancer Treatments Project Group is based on a tight network of 6 institutions (status Sept. 2013) with expertise in early clinical trials (first in human, phase I, early phase II);
  • Each center has dedicated human (at least one trained physician, data manager and research nurse) as well as structural resources (outpatient / inpatient facilities, lab equipment) to perform such trials including pharmacokinetic and pharmacodynamic evaluations;
  • Each center has a reference pathology institution whose the list of the available diagnostic assays for assessing molecular markers has been defined;
  • Patients can be referred from one site to another where a specific trial is open.
  • The SAKK Coordinating Center (SAKK CC) has set up a dedicated structure to coordinate the activities of the New Anticancer Treatments Project Group and to implement them within the phase I trials.
  • The SAKK CC has finalized a master clinical trial agreement of collaboration with pharmaceutical companies for new drugs development in which only short and fast trial specific appendices are needed before starting
  • The SAKK aims preliminary for investigator initiated trials, however, we also conduct phase I and first in human trials where a pharmaceutical company is sponsor.;
  • A procedure for fast track approval of the proposals by the SAKK Board has been implemented.